Hepagene vaccine and immunotherapeutic data

MDV unveiled positive Phase II results showing that Hepagene protects against hepatitis B when existing vaccines are inadequate and is effective as a one-month/two dose regimen.

The trial was a double-blind study of Hepagene compared to SmithKline Beecham’s Engerix B in 90 subjects who had a history of at least three previous injections of Engerix B and who then received a further 20 µg dose of Engerix B and still responded inadequately. They were randomized to receive either another dose of Engerix B or the first dose of Hepagene. ...